EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of Second-Line Nivolumab Versus Other Therapies in Metastatic Renal Cell Carcinoma

Ece Sahin Hafizoglu, Faruk Recep Ozalp, Ferhat Ekinci, Huseyin Salih Semiz, Mustafa Sahbazlar, Atike Pinar Erdogan

Journal of Clinical Medicine · 14.11.2026 · 15 (22) · 8915

DOI: 10.3390/jcm15228915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.11.2026. Verfasst von Ece Sahin Hafizoglu und 5 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to compare the real-world outcomes of second-line nivolumab with those of other second-line systemic therapies in patients with metastatic renal cell carcinoma (mRCC) who progressed after first-line systemic therapy. Materials and Methods: Data from 147 mRCC patients followed up across two centers between January 2015 and June 2025 were retrospectively analyzed. Patients were grouped according to their second-line regimen into the nivolumab group (n = 73) and the other therapies group (n = 74; predominantly axitinib and everolimus). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Associations were evaluated using Cox regression models with covariates prespecified on clinical grounds, and robustness was assessed in sensitivity analyses addressing treatment era, subsequent therapy, histology, and the PFS definition.

Results

Median OS was 22 months in the nivolumab group and 17 months in the other therapies group; this unadjusted difference was not statistically significant (log-rank p = 0.051), nor was the difference in restricted mean survival time up to 60 months (6.0 months, p = 0.118). Median PFS was 10.0 and 6.4 months, respectively (p = 0.011). In the primary multivariable model, receipt of other second-line therapies was associated with worse OS (HR: 1.694, 95% CI: 1.105–2.597) and PFS (HR: 1.972, 95% CI: 1.320–2.946) compared with nivolumab. The OS association was consistent in direction in sensitivity analyses, including an analysis restricted to patients who started second-line therapy from 2018 onward (HR: 2.081, 95% CI: 1.080–4.007), but was attenuated and no longer statistically significant when subsequent therapy was modelled as a time-dependent covariate (HR: 1.416, 95% CI: 0.949–2.112). In the comparator group, 21.6% of patients subsequently received nivolumab.

Conclusions

In this real-world cohort, second-line nivolumab was associated with lower adjusted hazards of death and progression than other second-line systemic therapies, although the unadjusted OS difference was not statistically significant. Given the observational design, the strong association between second-line treatment and treatment era, and differences in subsequent therapy, these findings should be interpreted as associations rather than causal treatment effects. They are most relevant to settings in which first-line TKI monotherapy remains in use.

Zitieren

APA

Hafizoglu, E. S., Ozalp, F. R., Ekinci, F., Semiz, H. S., Sahbazlar, M., & Erdogan, A. P. (2026). Real-World Outcomes of Second-Line Nivolumab Versus Other Therapies in Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine, 15(22), 8915. https://doi.org/10.3390/jcm15228915

Vancouver

Hafizoglu ES, Ozalp FR, Ekinci F, Semiz HS, Sahbazlar M, Erdogan AP. Real-World Outcomes of Second-Line Nivolumab Versus Other Therapies in Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine. 2026;15(22):8915. doi:10.3390/jcm15228915

BibTeX
@article{Hafizoglu2026,
  author = {Hafizoglu, Ece Sahin and Ozalp, Faruk Recep and Ekinci, Ferhat and Semiz, Huseyin Salih and Sahbazlar, Mustafa and Erdogan, Atike Pinar},
  title = {Real-World Outcomes of Second-Line Nivolumab Versus Other Therapies in Metastatic Renal Cell Carcinoma},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {8915},
  doi = {10.3390/jcm15228915}
}
Kostenlos starten →